ACADIA Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019

SAN DIEGO—(BUSINESS WIRE)—Dec. 20, 2018—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 37^th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019, at 11:00 a.m. Pacific Standard Time, followed by a question and answer breakout session at 11:30 a.m.

A live webcast of ACADIA’s presentation and breakout session will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through February 6, 2019.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and is commercializing the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. In addition, ACADIA has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia inadequate response, schizophrenia-negative symptoms, major depressive disorder and Rett syndrome. This press release and further information about ACADIA can be found at: www.acadia-pharm.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181220005196/en/

Source: ACADIA Pharmaceuticals Inc.

Investor Contact:
ACADIA Pharmaceuticals Inc.
Elena Ridloff, CFA
(858) 558-2871
[email protected]

Media Contact:
ACADIA Pharmaceuticals Inc.
Maurissa Messier
(858) 768-6068
[email protected]